Paul, Weiss Adds Antitrust Partner in Washington

Paul, Weiss, Rifkind, Wharton & Garrison LLP announced today that Christopher M. Wilson has joined the firm as a partner in the Litigation Department, resident in Washington. A former trial lawyer of the U.S. Department of Justice’s Antitrust Division, Wilson advises clients on a full range of antitrust matters, including merger control, cross-border antitrust investigations and private party litigation involving complex antitrust and consumer protection issues.

“I’m delighted to welcome Chris, a dynamic and talented antitrust advisor, to the partnership,” said Paul, Weiss Chairman Brad S. Karp. “Chris will further deepen our leading global antitrust and merger clearance capabilities, at a time when our clients are navigating an increasingly complex antitrust landscape.”

“Chris’s time at the Antitrust Division has been distinguished by a remarkable track record of achievements. He will be a fantastic addition to the firm and his expertise will further solidify our presence in Washington,” said Andrew C. Finch, global co-chair of the Antitrust Practice.

Wilson has handled numerous major merger reviews before the FTC and the DOJ, and advises on matters implicating the Sherman Act, the Clayton Act, the FTC Act and the Hart-Scott-Rodino (HSR) merger review process, as well as international and state competition statutes. His representations include, among others, Pioneer Natural Resources in its acquisition by ExxonMobil; Platinum Equity in its acquisition of Solenis; GE Healthcare in its acquisition of BK Medical; Xylem in its acquisition of Evoqua; Spark Therapeutics in its acquisition by Roche; and Stone Canyon Industries in its acquisition of Morton Salt. He has also handled cross-border investigations involving the European Union, the United Kingdom, Canada, Brazil, Japan, Korea and Saudi Arabia, among other jurisdictions. His work has involved a wide range of industries, including health insurance, transportation, telecommunications, technology, energy, agriculture and biotechnology.

“Chris is a commercial, thoughtful advisor who has managed numerous major merger reviews, both within the DOJ and in private practice,” said Scott A. Sher, global co-chair of the Antitrust Practice. “His addition will benefit our clients across a range of industries, and we are thrilled that he is joining us.”

Prior to private practice, Wilson was a trial attorney in the Transportation, Energy & Agriculture Section of the U.S. Department of Justice’s Antitrust Division, where he played a prominent role in numerous high-profile matters, and was twice awarded the Division’s Award of Distinction. During his time at the DOJ, Wilson investigated numerous high-profile transactions, including CVS/Aetna, Bayer/Monsanto, Alaska Airlines/Virgin America, Aetna/Humana, Anthem/Cigna and Halliburton/Baker Hughes. He is an active member of the ABA Antitrust Section’s Transportation & Energy Industries Committee, and has published in Competition Law International, The Antitrust Health Care Chronicle, The M&A Lawyer, and other antitrust newsletters and publications.

“I am thrilled to be joining Paul, Weiss, a firm known for its inclusive and collaborative culture, and look forward to working with the firm’s top-notch clients and incredibly talented lawyers,” Wilson said.

Wilson earned a B.A. from New York University and a J.D. from Columbia University, where he was a Harlan Fiske Stone scholar, and served as an editor on the Columbia Business Law Review.

The Paul, Weiss Antitrust Practice advises clients on a full range of global antitrust matters, including antitrust regulatory clearance, government investigations, private litigation, and counseling and compliance. The firm represents clients before antitrust and competition authorities in the United States, the European Union, the United Kingdom and other jurisdictions around the world.